Recipient of a royal award

ประกาศผลในวันที่ 14 มีนาคม 2567

image 45

Abass Alavi, MD, MD(Hon), PHD(Hon), DSc(Hon)

Professor of Radiology at the Hospital of the University of Pennsylvania

Associate Director at the Institute on Aging at the University of Pennsylvania Perelman School of Medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

นายสมมติ สกลุไทย

รางวัลสาขา medicine

Biography of the Royal Award Recipient

ศาสตราจารย์ ดร. นายแพทย์ เดนนิส เจ. สเลมอน

(Professor Dr. Dennis J. Slamon)​

Biography and Achievements

          Professor Dennis J. Slamon is an Americanphysician expertise in oncology and cell biology who discovered Human
Epidermal Growth Factor Receptor 2 (HER2) -oncogene, which led to the development of Trastuzumab, a groundbreaking
molecular drug for HER2-positive that has saved the lives of millions of women worldwide. His discovery marked a paradigm
shift in cancer treatment, ushering the era of personalized and precision medicine.

Education
          Professor DennisSlamon was born on August 6, 1948, in Newcastle, Pennsylvania, USA. He became interested in
biology and medicine at ayoung age. In 1970, he received a Bachelor of Arts in Biology from Washington & Jefferson College.
In 1975, he graduated with honors from the University of Chicago Pritzker School of Medicine and earned his PhD in Cell
Biology in the same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics in 1979
and served as a Chief Resident that same year. He received an American Board of Internal Medicine in 1978 and Medical
Oncology in 1981. He completed his fellowship in Hematology/Oncology at UCLA School of Medicine in 1982.

Career
          Professor Dennis Slamon currently serves as the Director of Clinical/Translational Research, and the Director of
Revlon/UCLA Women’s Cancer Research Program at the Jonsson Comprehensive Cancer Center. He is also a Professor of
Medicine, the Chief of the Division of Hematology/Oncology and the Executive Vice Chair for Research in the Department of
Medicine at UCLA. Additionally, he serves as the Director of the Medical Advisory Board for the National Colorectal Cancer
Research Alliance, a fundraising organization promoting advancements in colorectal cancer research.

Achievements
          Professor Dennis Slamon and his research team conducted a 12-year study on the mechanisms underlying breast
cancer and the development of therapeutic agents to inhibit those mechanisms. He utilized monoclonal antibodies to identify
genetic abnormalities responsible for controlling cell growth. One of the key genes identified was HER2 (Human Epidermal
Growth Factor Receptor 2) which is overexpressed in approximately 25% of all breast cancer patients. The overexpression of
HER2 was found to be a critical driver of disease aggressiveness, leading to rapid relapsesand mortality among affected patients.
          Professor Slamon together with Dr. Axel Ullrich, discovered that introducing a monoclonal antibody to HER2-positive
breast cancer cells halted their growth and division. When the antibody was removed, the cancer resumed proliferation. This
specific antibody was later named Trastuzumab, which led to the development of the drug Trastuzumab, commercially known
as Herceptin. Trastuzumab became the first therapeutic agent capable of targeting and inhibiting the HER2-positive driven
pathway in breast cancer, it works by binding to the HER2 receptors on the surface of cancer cells, blocking the signals that
promote cell proliferation, and ultimately leading to cancer cell death.
          Despite a lack of funding for clinical trials at the beginning and Dr. Ullrich’s return to Germany, Professor Slamon
secured adequate financial support the clinical trials. After completing three phases of clinical trials, Trastuzumab has proven
effective in both controlling metastatic disease and preventing recurrence in early-stage breast cancer, thereby extending
survival of patients with advanced disease and increasing the likelihood of cure in early-stage cases.
          In 1998, Trastuzumab was approved by the U.S. Food and Drug Administration (FDA),becoming the first genetically
targeted therapy for cancer. Today, it remains a cornerstone in the treatment of HER2-positive breast cancer worldwide and
ongoing research continues to refine and enhance the efficacy of HER2-target therapies.
          The discovery of Trastuzumab opened new research pathways, leading to numerous targeted therapies that use
antibodies to attack cancer at its genetic roots. Professor Slamon also pioneered research on estrogen receptor-positive breast
cancer, which led to the development of an entirely new class of anti-cancer drugs known CDK4/6 inhibitors. He currently
leads the global NATALEE study, evaluating Ribociclib as part of treatment for early-stage estrogen receptor-positive breast
cancer. As a result of his contributions, approximately 85% of all patients with metastatic breast cancer now benefit from
treatments originating from his work. He remains at the forefront of cancer research, exploring new personalized treatment
strategies and pursuing innovative approaches to combat this complex disease.

Awards
          To acknowledge his contributions President Bill Clinton appointed Professor Dennis Slamon to the three-member
President’s Cancer Panel in June 2000. Professor Dennis Slamon has received numerous national and international awards
recognizing his scientific achievements. These include:
          2000 – Translational Medicine Award from the USCD-Salk Institute and the Bristol-Myers Squibb Oncology
Millennium Award for significant achievement and leadership in breast cancer research
          2001- Wadsworth Center’s Brown-Hazen Award for Excellence in the Basic Sciences
          2002- Jacob Heskel Gabbay Award in Biotechnology and Medicine
          2004- Medal of Honor from the American Cancer Society
          2007- GairdnerFoundation International Award for his work in the development of Herceptin
          2019- Lasker-DeBakey Clinical Medical Research Award
          2021- Warren Alpert Foundation Scientific Prize
         2024-Szent-Györgyi Prize for Progress in Cancer Research
         2024-Sjöberg Prize from the Royal Swedish Academy of Sciences
         2024- UCD Ulysses Medal from the University College Dublin.
         Professor DennisSlamon remains actively engaged in his scientific work with unwavering passion. In recognition of
his revolutionary contributions and leadership in molecular breast cancer research and treatment as well as his profound impact
on improving outcomes for cancer patients worldwide, the Board of Trustees of the Princess Chulabhorn Award Foundation
unanimously agreed that Professor Dennis J. Slamon is the recipient of the Princess Chulabhorn Award for the year 2024.       

Scroll to Top